Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 1,001–1,100 of 3,636
Naoum, I., Saliba, W., Aker, A., & Zafrir, B. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.05.003 · Cited by 23
Yamamoto, T., Sugizaki, Y., Kawamori, H., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-24-0480 · Cited by 19
Cannon, C. P., Sanchez, R. J., Klimchak, A. C., Khan, I., Sasiela, W. J., Reynolds, M. R., & Rosenson, R. S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.01.028 · Cited by 21
Self-citationAmarenco, P., Kim, J. S., Labreuche, J., Giroud, M., Lee, B., Mahagne, M., Nighoghossian, N., Simon, T., Steg, P. G., Touboul, P., et al. (2019) · European Stroke Journal · doi:10.1177/2396987319838100 · Cited by 21
Self-citationNtaios, G., & Milionis, H. J. (2019) · International Journal of Stroke · doi:10.1177/1747493019851283 · Cited by 23
Kongpakwattana, K., Ademi, Z., Chaiyasothi, T., Nathisuwan, S., Zomer, E., Liew, D., & Chaiyakunapruk, N. (2019) · PharmacoEconomics · doi:10.1007/s40273-019-00820-6 · Cited by 23
Lan, N. S. R., Fegan, P. G., Rankin, J. M., Bell, D. A., Watts, G. F., & Yeap, B. B. (2019) · Diabetic Medicine · doi:10.1111/dme.14095 · Cited by 19
Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations
Heine, G. H., Eller, K., Stadler, J. T., Rogacev, K. S., & Marsche, G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107459 · Cited by 20
Omori, H., Ota, H., Hara, M., Kawase, Y., Tanigaki, T., Hirata, T., Sobue, Y., Okubo, M., Kamiya, H., & Matsuo, H. (2020) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.02.019 · Cited by 19
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 25
Gurevitz, C., Auriel, E., Elis, A., & Kornowski, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030536 · Cited by 21
“[37,38] The ODYSSEY OUTCOMES STUDY reported 9 (<0.”
BackgroundJia, X., Rifai, M. A., Birnbaum, Y., Smith, S. C., & Virani, S. S. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0784-8 · Cited by 19
Ray, K. K. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1008 · Cited by 20
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies
Catapano, A. L., Mikhailova, E., Navar, A. M., Banka, P., Corral, P., Saxena, M., Steg, P. G., Verma, S., Kordahi, A. Y., Mendizabal, G., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.036 · Cited by 19
Self-citationArmario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.02.001 · Cited by 22
Wu, L., Zhang, B., Li, C., Zhuang, Z., Liu, K., Chen, H., Zhu, S., Zhu, J., Dai, Z., Huang, H., et al. (2024) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-332392 · Cited by 21
Lp(a): A Rapidly Evolving Therapeutic Landscape
Anchouche, K., & Thanassoulis, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01252-0 · Cited by 22
“…receptor (LDLR) thereby enhancing the hepatic clearance of circulating LDL particles, have demonstrated in the FOURIER and ODYSSEY trials an ability to reduce LDL cholesterol by up to 40–60% among secondary prevention patients with suboptimal LDL despite already being on statin therapy [19, 20 ].”
PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
Abduljabbar, M. H. (2024) · Pharmaceuticals · doi:10.3390/ph17121581 · Cited by 23
Sampson, M. L., Zubirán, R., Wolska, A. T., Meeusen, J. W., Donato, L. J., Jaffe, A. S., Melloni, G. E. M., Giugliano, R. P., Sabatine, M. S., Marston, N., et al. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf073 · Cited by 20
Ferrières, J., Bataille, V., Puymirat, É., Schiele, F., Simon, T., Danchin, N., & for the FAST‐MI investigators (2020) · Clinical Cardiology · doi:10.1002/clc.23437 · Cited by 20
“Cardiovascular disease (CVD), remains the most common cause of death worldwide.1 High-intensity statin treatment reduces the risk of Atheroclerotic Cardiovascular Disease (ASCVD) events in both primary and secondary prevention,2 but substantial residual risk remains even after significant reductions in low-density lip…”
BackgroundMarcusa, D. P., Giugliano, R. P., Park, J., de Lemos, J. A., Cannon, C. P., & Sabatine, M. S. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.6184 · Cited by 20
Stroke Genetics: Turning Discoveries into Clinical Applications
Dichgans, M., Beaufort, N., Debette, S., & Anderson, C. D. (2021) · Stroke · doi:10.1161/strokeaha.121.032616 · Cited by 21
Current management and prognosis of patients with recurrent myocardial infarction
Luca, L. D., Paolucci, L., Nusca, A., Putini, R. L., Mangiacapra, F., Natale, E., Ussia, G. P., Colivicchi, F., Grigioni, F., Musumeci, F., et al. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203080 · Cited by 23
Liu, H., Shen, J., Li, S., Song, Y., & Ju, M. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/9648708 · Cited by 20
“Every year, more than 15 million individuals worldwide die from cardiovascular disease [1].”
BackgroundRetractedNew Approaches to Cardiovascular Disease and Its Management in Kidney Transplant Recipients
Aziz, F., Jorgenson, M., Garg, N., Parajuli, S., Mohamed, M., Raza, F., Mandelbrot, D. A., Djamali, A., & Dhingra, R. (2021) · Transplantation · doi:10.1097/tp.0000000000003990 · Cited by 23
Vallejo‐Vaz, A. J., Bray, S. L., Villa, G., Brandts, J., Kiru, G., Murphy, J., Banach, M., Servi, S. D., Gaiță, D. I., Gouni‐Berthold, I., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07343-x · Cited by 23
Self-citationLipids, lipid-lowering therapy, and neuropathy: a narrative review
Pasha, R., Azmi, S., Ferdousi, M., Kalteniece, A., Bashir, B., Gouni-Berthold, I., Malik, R. A., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.03.013 · Cited by 18
Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
Rikhi, R. R., & Shapiro, M. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154611 · Cited by 19
“One of the methods for inhibiting PCSK9 is with fully human monoclonal antibodies, of which alirocumab and evolocumab have been well studied in secondary prevention trials, Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab (ODYSSEY OUTCOMES) and Further Cardiovascu…”
BackgroundMethodEngebretsen, I., Munkhaugen, J., Bugge, C., Halvorsen, S., Ødegaard, K. M., Støvring, H., & Kristiansen, I. S. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac070 · Cited by 20
Sekkarie, A., Park, S.-Y., Therrien, N. L., Jackson, S. L., Woodruff, R. C., Attipoe-Dorcoo, S., Yang, P. K., Sperling, L. S., Loustalot, F. V., & Thompson‐Paul, A. M. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2022.10.010 · Cited by 18
Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges
Gianazza, E., Brioschi, M., Iezzi, A., Paglia, G., & Banfi, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043291 · Cited by 24
“Based on evidence from the two major clinical trials on PCSK9 inhibitors, the FOURIER [104] and the ODYSSEY [106] outcome trials that used evolocumab and alirocumab, respectively, as fully humanized monoclonal antibodies against PCSK9, a recent paper by Gallego-Colon et al. underlines that the 2019 European Society of…”
Pham, V., Moroni, A., Gall, E., Benedetti, A., Zivelonghi, C., & Picard, F. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082833 · Cited by 28
“The first anti-PCSK9 antibodies, alirocumab and evolocumab, were associated with a dramatic decrease in low-density lipoprotein-cholesterol (LDL-C) levels and MACE by approximately 60% and 20%, respectively [55,56].”
BackgroundEpigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes
Whittaker, M. N., Testa, L. C., Quigley, A., Jindal, I., Cortez-Alvarado, S. V., Qü, P., Yang, Y., Alameh, M., Musunuru, K., & Wang, X. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319748 · Cited by 21
Present and Future of Dyslipidaemia Treatment—A Review
Merćep, I., Vujević, A., Strikić, D., Radman, I. B., Pećin, I., & Reiner, Ž. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185839 · Cited by 25
Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
Reiner, Ž. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0773-y · Cited by 18
Dijk, W., & Cariou, B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13636 · Cited by 19
“However, no studies have so far demonstrated differences in the incidence of NOD in normoglycaemic or pre-diabetic individuals treated with alirocumab or evolocumab treatment placebo (see Table 2).(15,60,61,92,93) In a pooled analysis of 10 ODYSSEY trials, the impact of alirocumab on NOD and pre-diabetes incidence in…”
BackgroundResultInfluentialLow LDL cholesterol—Friend or foe?
Hartz, J. C., Hegele, R. A., & Wilson, D. P. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.006 · Cited by 19
Chaiyasothi, T., Nathisuwan, S., Dilokthornsakul, P., Vathesatogkit, P., Thakkinstian, A., Reid, C. M., Wongcharoen, W., & Chaiyakunapruk, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00547 · Cited by 19
Luca, L. D. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07027-4 · Cited by 22
Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects
Li, J., Liu, H.-H., Wu, N., Yeo, K. K., Tan, K. C. B., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Baek, S. H., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1802426 · Cited by 22
Jia, X., Liu, J., Mehta, A., Ballantyne, C. M., & Virani, S. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07082-x · Cited by 19
Sagris, D., Ntaios, G., Georgiopoulos, G. A., Kakaletsis, N., Elisaf, M., Katsiki, N., Korompoki, E., Kypreos, K. E., Boutari, C., Bilianou, H. I., et al. (2020) · International Journal of Stroke · doi:10.1177/1747493020971970 · Cited by 18
“93 for alirocumab).(37,40) Subgroup analyses of the FOURIER and ODYSSEY OUTCOMES trials involving patients with a history of stroke confirmed a benefit in the reduction of CV events and a numerical decrease in the rate of stroke recurrence.”
BackgroundValensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.07.003 · Cited by 20
“type 9 (PCSK9) inhibitors, which have been shown to significantly reduce CV events, must be discussed [193,194].”
BackgroundBhagavathula, A. S., Matrooshi, N. O. A., Clark, C. C. T., & Rahmani, J. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00989-1 · Cited by 20
Vallejo‐Vaz, A. J., Packard, C. J., Ference, B. A., Santos, R. D., Kastelein, J. J. P., Stein, E. A., Catapano, A. L., Pedersen, T. R., Watts, G. F., & Ray, K. K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.01.003 · Cited by 20
Novel Experimental Agents for the Treatment of Hypercholesterolemia
Pećin, I., & Reiner, Ž. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267376 · Cited by 21
Alonso, R., Muñiz-Grijalvo, O., Díaz-Díaz, J. L., Zambón, D., de Andrés, R., Arroyo-Olivares, R., Fuentes, F. J., Muñoz-Torrero, J. F. S., Cepeda, J. M., Aguado, R., et al. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.04.011 · Cited by 20
Ma, W., Guo, X., Ma, Y., & Hu, Z. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.008 · Cited by 18
Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia
Salaheldin, T. A., Godugu, K., Bharali, D. J., Fujioka, K., Elshourbagy, N. A., & Mousa, S. A. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102480 · Cited by 18
Hussain, A., & Ballantyne, C. M. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-100119-013612 · Cited by 22
Jia, X., & Virani, S. S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012352 · Cited by 20
Muntner, P., Ghazi, L., Jones, J., Dhalwani, N. N., Poudel, B., Wen, Y. R., Chen, L., Wang, Z., Bittner, V., Kalich, B. A., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02868-z · Cited by 22
“In randomized controlled trials, proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies (PCSK9i mAb) and eze-timibe each lowered low-density lipoprotein cholesterol (LDL-C) and reduced the risk for atherosclerotic cardiovascular disease (ASCVD) events [1–3].”
Self-citationAl-Awar, A., & Hussain, S. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2911398 · Cited by 22
Palumbo, M., Ugolotti, M., Zimetti, F., & Adorni, M. P. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.12.004 · Cited by 21
“Currently, three PCSK9 inhibitors are available in market: two monoclonal antibodies alirocumab and evolocumab [30,31], and a small interfering RNA (siRNA), namely inclisiran, that inhibits the synthesis of PCSK9 protein in the liver [32].”
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Tramontano, D., Bini, S., Maiorca, C., Di Costanzo, A., Carosi, M., Castellese, J., Arizaj, I., Commodari, D., Covino, S., Sansone, G., et al. (2025) · Drugs · doi:10.1007/s40265-025-02158-0 · Cited by 17
“Alirocumab and evolocumab have demonstrated robust LDL-C reductions and improved cardiovascular outcomes in large-scale trials [52, 53], with post hoc sub-analyses indicating similar RR reductions across varying CKD stages, although these studies largely excluded individuals with advanced CKD [55,…”
Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02389-2 · Cited by 17
“However, its scope is limited in ASCVD patients, as it does not lower LDL, a crucial component in ASCVD pathogenesis [58–61].”
Brown, T. M., Bittner, V., Colantonio, L. D., Deng, L., Farkouh, M. E., Limdi, N. A., Monda, K. L., Rosenson, R. S., Șerban, M.-C., Somaratne, R. M., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.004 · Cited by 17
Self-citationGayoso-Rey, M., Díaz-Trastoy, O., Romero‐Ventosa, E. Y., García‐Beloso, N., González-Freire, L., Lorenzo‐Lorenzo, K., Gil, B., Carballeira, R. P., Amaro, M. B., López-Gil-Otero, M. D. M., et al. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.02.002 · Cited by 16
Ruiz, M. B., Amaya‐Pascasio, L., Chacón, R. D. T., Soria, M. J. Á., Padillo, A. A., Bailén, M. C., Pinilla, R. M., Ortega, I. P., Rodríguez, B. S., Zumarraga, L. A. A., et al. (2021) · Atherosclerosis Plus · doi:10.1016/j.athplu.2021.08.009 · Cited by 19
“Combinations of PCSK9i with statins and/or ezetimibe [8,9] may benefit patients who fail to achieve the expected therapeutic goals despite tolerable optimal treatment, as well as those who cannot tolerate standard medications.”
BackgroundResultEffect of Parathyroidectomy on Metabolic Homeostasis in Primary Hyperparathyroidism
Frey, S., Bourgade, R., May, C. L., Croyal, M., Bigot‐Corbel, E., Renaud-Moreau, N., Wargny, M., Caillard, C., Mirallié, É., Cariou, B., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051373 · Cited by 20
“Therefore, therapeutic inhibition of circulating PCSK9 with human monoclonal antibodies (alirocumab and evolocumab) has been quickly developed to lower plasma LDL-C levels and CV events [24,25].”
BackgroundDifferential cholesterol uptake in liver cells: A role for PCSK9
Luquero, A., Vilahur, G., Casaní, L., Badimón, L., & Borrell-Pagés, M. (2022) · The FASEB Journal · doi:10.1096/fj.202101660rr · Cited by 19
Donald, D. R., Reynolds, V. W., Hall, N., DeClercq, J., & Choi, L. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.03.004 · Cited by 18
Tandirerung, F. J. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01783-5 · Cited by 20
Farnier, M., Santos, R. D., Cosín-Sales, J., Владиславович, Е. М., Liu, J., Granados, D., Santoni, S., Khan, I., & Catapano, A. L. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac214 · Cited by 23
Wei, T. L., & Cho, L. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000856 · Cited by 20
Wang, H., Mao, Y.-C., Xu, X., Zhao, S., Han, D.-D., Ge, S., Song, K., Geng, C., & Tian, Q. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1016802 · Cited by 21
“Several studies have found that PCSK9 inhibitors over time enhanced the beneficial cardiovascular effects (32, 37, 41).”
BackgroundZhou, Z., Zhang, W., Burgner, D. P., Tonkin, A. M., Zhu, C., Sun, C., Magnussen, C. G., Ernst, M. E., Breslin, M. C., Nicholls, S. J., et al. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.02.025 · Cited by 18
Park, J. S., Cho, K. H., Hong, Y. J., Kim, M. C., Sim, D. S., Kim, J. H., Ahn, Y., & Jeong, M. H. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e102 · Cited by 20
Rezaianzadeh, A., Moftakhar, L., Seif, M., Johari, M. G., Hosseini, S. V., & Dehghani, S. S. (2023) · Tropical Medicine and Health · doi:10.1186/s41182-023-00527-7 · Cited by 26
“Two clinical trial studies have shown that the risk of developing CVDs in patients with dyslipidemia is reduced by treating these individuals with a statin drug that reduces dyslipidemia [31, 32].”
BackgroundBurger, P. M., Dorresteijn, J. A. N., Fiolet, A. T. L., Koudstaal, S., Eikelboom, J. W., Nidorf, S. M., Thompson, P. L., Cornel, J. H., Budgeon, C. A., Westendorp, I. C. D., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad221 · Cited by 19
Self-citationMutschlechner, D., Tscharre, M., Huber, K., & Gremmel, T. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad052 · Cited by 20
Dugré, N., Lindblad, A. J., Perry, D., Allan, G. M., Braschi, É., Falk, J., Froentjes, L. S., Garrison, S., Kirkwood, J. E. M., Korownyk, C. S., et al. (2023) · Canadian Family Physician · doi:10.46747/cfp.6910701 · Cited by 25
“Evidence for PCSK9 inhibitors comes mostly from 2 large RCTs 72,73 looking specifically at secondary cardio-vascular prevention using a maximum tolerated dose of statin.”
BackgroundLandmesser, U., Köenig, W., Leiter, L. A., Raal, F. J., Ray, K. K., Wright, R. S., Han, J., Conde, L. G., & Schwartz, G. G. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117354 · Cited by 20
Self-citationKrychtiuk, K. A., Marquis‐Gravel, G., Murphy, S., Alexander, K. P., Chiswell, K., Green, J. B., Leiter, L. A., Lópes, R. D., Prato, S. D., Jones, W. S., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae006 · Cited by 21
Dyslipidemia Treatment and Cerebrovascular Disease: Evidence Regarding the Mechanism of Stroke
Ha, S. H., & Kim, B. J. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.2.139 · Cited by 28
Khan, A. W., Aziz, M., Sourris, K. C., Lee, M. K., Dai, A., Watson, A. M. D., Maxwell, S., Sharma, A., Zhou, Y., Cooper, M. E., et al. (2024) · Diabetes · doi:10.2337/db23-0167 · Cited by 21
Zhang, Y., Pei, Z., Chen, B., Qu, Y., Dong, X., Yu, B., Wang, G., Xu, F., Lu, D., He, Z., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107340 · Cited by 18
Medications for Lipid Control: Statins vs Newer Drugs
McPherson, R., Adreak, N., & Sharma, A. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.05.004 · Cited by 33
“26 Generally, these agents were well received, with rare injection site reactions.”
Uehara, H., Kajiya, T., Abe, M., Nakata, M., Hosogi, S., & Ueda, S. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae055 · Cited by 17
Hyperlipidemia and cardiovascular disease: new insights on lipoprotein(a)
Burkhardt, R. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000594 · Cited by 17
Therapeutic management of hyperlipoproteinemia (a)
Kosmas, C. E., Sourlas, A., Mallarkey, G., Silverio, D., Garcia, D. Y., Montan, P. D., Guzman, E., & Garcia, M. J. (2019) · Drugs in Context · doi:10.7573/dic.212609 · Cited by 19
Sundbøll, J., Larsen, A. P., Veres, K., Adelborg, K., & Sørensen, H. T. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.09.034 · Cited by 17
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at “Extreme” ASCVD Risk
Rosenblit, P. D. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1246-y · Cited by 24
Ramasamy, A., Safi, H., Moon, J., Andiapen, M., Rathod, K. S., Maurovich‐Horvat, P., Bajaj, R., Serruys, P. W. J. C., Mathur, A., Baumbach, A., et al. (2020) · Cardiology · doi:10.1159/000506537 · Cited by 17
Prevalence of poor lipid control in patients with premature coronary artery disease
Martínez‐Sánchez, F. D., Galarza, E. J., Posadas‐Romero, C., Medina-Urrutia Aida, X., Martínez-Alvarado, M. R., Osorio‐Alonso, H., & Juárez-Rojas, J. G. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.04.030 · Cited by 18
Wang, Q., & Liang, C. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000914 · Cited by 22
Ying, Q., Chan, D. C., & Watts, G. F. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.603910 · Cited by 17
Statin intolerance: new data and further options for treatment
Diaconu, C. C., Iorga, R., Furtunescu, F., Katsiki, N., Stoian, A. P., & Rizzo, M. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000874 · Cited by 17
“The combination of statins with a proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, such as evolocumab or alirocumab, was also reported to safely reduce CVD risk, by improving CVD outcomes, in the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk trial [31] an…”
BackgroundNanchen, D., Carballo, D., Bilz, S., Rickli, H., Koskinas, K. C., Mach, F., Mueller, C. E., Crljenica, C., Rossi, M., Reichert, N., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01962-w · Cited by 20
Xu, B., Xu, Z., Xu, D., & Tan, X. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02342-6 · Cited by 20
“However, as fibrates [59] and PCSK9 inhibitors [60] not only reduce TG, similar to EPA, but also increase HDL and reduce LDL, a new debate arises as to whether we should use fibrates instead of EPA or PCSK9 inhibitors instead of a statin/EPA combination [61].”
BackgroundUndertreatment or Overtreatment With Statins: Where Are We?
García-Fernández-Bravo, I., Torres-Do-Rego, A., López-Farré, A. J., Valle, F. G., Rodríguez, P. D., & Alvarez-Sala-Walther, L. A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.808712 · Cited by 23
“High-dose statin therapy has shown impressive benefits in plaque reduction that has been postulated to be due to its anti-inflammatory effects in addition to its intensive LDL-C-lowering effects (1, 2).”
BackgroundInfluentialLandmesser, U., McGinniss, J., Steg, P. G., Bhatt, D. L., Bittner, V. A., Diaz, R., Dilic, M., Goodman, S. G., Jukema, J. W., Loy, M., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac107 · Cited by 17
Self-citationBell, A. S., Rosoff, D. B., Mavromatis, L. A., Jung, J., Wagner, J., & Lohoff, F. W. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026122 · Cited by 17
Patel, A. P., & Natarajan, P. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz032 · Cited by 20
Maximizing the benefits of cholesterol-lowering drugs
Feingold, K. R. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000631 · Cited by 19
Waiting List and Kidney Transplant Vascular Risk: An Ongoing Unmet Concern
Hernández, D., Alonso-Titos, J., Armas-Padrón, A. M., López, V., Cabello, M., Sola, E., Fuentes, L., Gutiérrez, E., Vázquez, T., Jiménez, T., et al. (2019) · Kidney & Blood Pressure Research · doi:10.1159/000504546 · Cited by 19
Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1750949 · Cited by 22
“The monoclonal antibody inhibitors of proprotein convertase subtilisin-kexin 9 (PCSK9), evolocumab and alirocumab, are very effective in reducing LDL cholesterol and they have shown benefits in the primary composite cardiovascular endpoints in the cardiovascular outcome studies, the FOURIER (Further Cardiovascular Out…”
BackgroundMotoyama, S., Nagahara, Y., Sarai, M., Kawai, H., Miyajima, K., Sato, Y., Matsumoto, R., Takahashi, H., Naruse, H., Ishii, J., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0615 · Cited by 17
PCSK9 deficiency alters brain lipid composition without affecting brain development and function
Pärn, A., Olsen, D., Tuvikene, J., Kaas, M., Borisova, E., Bilgin, M., Elhauge, M., Vilstrup, J., Madsen, P., Ambrozkiewicz, M. C., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1084633 · Cited by 16
“Accordingly, PCSK9 siRNA and monoclonal antibodies blocking the PCSK9/LDLR interaction potently lower LDL cholesterol and reduce the risk of adverse cardiovascular events (Sabatine et al., 2017; Schwartz et al., 2018; Ray et al., 2020).”
Background
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

